SCHEMBL734381

SCHEMBL734381

CC(C)=CB(O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1986484 0.89
SCHEMBL1331313 0.55
SCHEMBL20475 0.55
SCHEMBL1276473 0.55 TSHR (0.36)
SCHEMBL935643 0.55
SCHEMBL18513525 0.52
SCHEMBL8410071 0.51
Ammonia Solution, Strong SCHEMBL10394131 0.51
Water SCHEMBL21954509 0.51
Ammonia Solution, Strong SCHEMBL3896205 0.51

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 282 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170226395-A1 THERMAL ENERGY STORAGE PHASE CHANGE MATERIALS COMPRISING BORONIC ACIDS AND METHODS OF MAKING AND USING THEM ENTROPY SOLUTIONS LLC (US) 2017-08-10 US claimed
WO-2016025536-A1 THERMAL ENERGY STORAGE PHASE CHANGE MATERIALS COMPRISING BORONIC ACIDS AND METHODS OF MAKING AND USING THEM ENTROPY SOLUTIONS INC. (US) 2016-02-18 WO claimed
EP-2230292-B1 Methods of lubricating transmissions AFTON CHEMICAL CORP (US) 2011-10-05 EP claimed
EP-1529831-B1 Lubricant compositions for power transmitting fluids AFTON CHEMICAL CORP (US) 2010-05-26 EP claimed
US-20250388565-A1 ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. 2025-12-25 US disclosed
EP-4655300-A1 PGDH INHIBITORS AND METHODS OF MAKING AND USING Epirium Bio Inc. (US) 2025-12-03 EP disclosed
US-20250353808-A1 5-METHOXYMETHYL AND 5-HYDROXYMETHYL PHENETHYLAMINES 2A BIOSCIENCES, INC. 2025-11-20 US disclosed
EP-3938340-B1 HETEROAROMATIC AND HETEROBICYCLIC AROMATIC DERIVATIVES FOR THE TREATMENT OF FERROPTOSIS-RELATED DISORDERS COLLABORATIVE MEDICINAL DEV LLC (US) 2025-07-09 EP disclosed
WO-2025111251-A1 COMPOUNDS THAT INHIBIT POLO-LIKE KINASE 4 EXELIXIS, INC. (US) 2025-05-30 WO disclosed
EP-4543871-A1 ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF Relay Therapeutics, Inc. (US) 2025-04-30 EP disclosed
CN-119650696-A Negative electrode material, preparation method thereof, negative electrode plate, battery and electronic device 江苏正力新能电池技术股份有限公司 2025-03-18 CN disclosed
WO-2025049419-A1 PYRAZOLYL COMPOUNDS AS EMOPAMIL BINDING PROTEIN INHIBITORS GENZYME CORPORATION (US) 2025-03-06 WO disclosed
WO-2006097817-A9 N- (N-SULFONYLAMINOMETHYL) CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN PFIZER JAPAN INC (JP) 2006-12-07 WO disclosed
WO-2006103503-A1 SUBSTITUTED ARYLOXOETHYL CYCLOPROPANECARBOXAMIDE COMPOUNDS AS VR1 RECEPTOR ANTAGONISTS PFIZER JAPAN INC. (JP) 2006-10-05 WO disclosed
WO-2006097817-A1 N- (N-SULFONYLAMINOMETHYL) CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN PFIZER JAPAN INC. (JP) 2006-09-21 WO disclosed
US-20060211741-A1 Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists PFIZER, INC. 2006-09-21 US disclosed
EP-1675859-A1 MODULATORS OF SEROTONIN RECEPTORS Bristol-Myers Squibb Company (US) 2006-07-05 EP disclosed
US-6924377-B2 Process for preparing highly functionalized γ-butyrolactams and γ-amino acids WARNER-LAMBERT COMPANY (US) 2005-08-02 US disclosed
WO-2005035533-A1 MODULATORS OF SEROTONIN RECEPTORS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-04-21 WO disclosed
US-20050080074-A1 Modulators of serotonin receptors BRISTOL-MYERS SQUIBB COMPANY 2005-04-14 US disclosed